Physician profile
Olivia Willey
NPI 1477744456
$3,845.73
in general payments reported to CMS, 2019-2025
47 companies · $68.14 in 2025
The $68.14 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,535 · 2022: $1,856 · 2023: $325 · 2024: $62.08 · 2025: $68.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $428.98 | 2021-2025 | Talvey, Rybrevant |
| Novartis Pharmaceuticals Corporation | $391.62 | 2021-2023 | |
| Lilly USA, LLC | $238.82 | 2021-2022 | |
| Amgen INC. | $237.01 | 2021-2022 | |
| Astellas Pharma US INC | $215.23 | 2021-2022 | |
| Genzyme Corporation | $214.40 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $174.18 | 2021-2024 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $149.19 | 2021-2023 | Enhertu |
| Seagen INC. | $143.58 | 2021-2023 | Adcetris, Tukysa |
| Incyte Corporation | $127.50 | 2022-2023 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $117.40 | 2022-2023 | Imbruvica |
| Celgene Corporation | $102.74 | 2022 | |
| Jazz Pharmaceuticals INC. | $90.84 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $80.35 | 2021-2025 | Libtayo |
| Dova Pharmaceuticals | $71.37 | 2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Willey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.